{"name":"InflaRx","slug":"inflarx","ticker":"IFRX","exchange":"NASDAQ","domain":"inflarx.de","description":"InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a a first-in-class monoclonal anti-human complement factor C5a antibody, which is in Phase 3 clinical trial for the treatment for patients suffering from early septic organ dysfunction, biological proof of concept was established, demonstrating its unique C5a blocking ability and selectivity; Izicopan, an oral, low molecular weight drug to target C5aR with high affinity and selectivity has completed completing Phase 2a trials; and IFX002, an advancement of vilobelimab technology, which is in preclinical development for the treatment of chronic inflammatory indications. It has co-development agreement with Staidson (Beijing) BioPharmaceuticals Co., Ltd.; Cell line sales agreement with Catalen","hq":"Jena, Germany","founded":0,"employees":"65","ceo":"Niels Riedemann","sector":"Immunology / Anti-Complement","stockPrice":2.42,"stockChange":-0.1,"stockChangePercent":-3.97,"marketCap":"$417M","metrics":{"revenue":34265.1869433,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":-50131308.45132001,"cash":46496130.87831841,"dividendYield":0,"peRatio":-5.5,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"CaCP29","genericName":"CaCP29","slug":"cacp29","indication":"Treatment of Hidradenitis Suppurativa","status":"phase_2"}]}],"pipeline":[{"name":"CaCP29","genericName":"CaCP29","slug":"cacp29","phase":"phase_2","mechanism":"CaCP29 is a monoclonal antibody targeting the complement system.","indications":["Treatment of Hidradenitis Suppurativa"],"catalyst":""}],"recentEvents":[{"date":"2024-02-27","type":"regulatory","headline":"InflaRx Announces FDA Fast Track Designation for Vilobelimab in Hidradenitis Suppurativa","summary":"InflaRx announced that the FDA has granted Fast Track designation to Vilobelimab for the treatment of hidradenitis suppurativa (HS).","drugName":"Vilobelimab","sentiment":"positive"},{"date":"2023-11-07","type":"earnings","headline":"InflaRx Reports Third Quarter 2023 Financial Results","summary":"InflaRx reported its third quarter 2023 financial results, with a net loss of $14.8 million.","drugName":"","sentiment":"neutral"},{"date":"2023-09-11","type":"deal","headline":"InflaRx Enters into Collaboration Agreement with Merck KGaA","summary":"InflaRx entered into a collaboration agreement with Merck KGaA to develop and commercialize Vilobelimab in certain territories.","drugName":"Vilobelimab","sentiment":"positive"}],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-02-06","type":"pipeline","source":"simplywall.st","summary":"Here's Why We're A Bit Worried About InflaRx's (NASDAQ:IFRX) Cash Burn Situation - simplywall.st","headline":"Here's Why We're A Bit Worried About InflaRx's (NASDAQ:IFRX) Cash Burn Situation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxNUklQTzFHOHYzTlZFNnExQWRQNU50RGd3RlBSeEcySmJETmVoczRwUkh2VEc1UHR5cHV6QjJ6RDJ3ZUN1RkJmb0phTnBXZEhjNlREcFUzV2x6bGhEaDRnMnFuaHA2VXBOTW1RdGV3MlJ1c1lMNnRyVEJLRjMwU2NPb0JMRGFDU2I3d19OU2JCRzJKYVJ6UW1hZ2k5bXloa1lKM2RBaVZ2MUdVMFBtNDNmNFdNbUNVQlE?oc=5","date":"2026-01-02","type":"pipeline","source":"RTTNews","summary":"Weekly Buzz: ARS Pharma's Neffy Goes East, SLS Advances, A Signal Of Hope For IFRX? - RTTNews","headline":"Weekly Buzz: ARS Pharma's Neffy Goes East, SLS Advances, A Signal Of Hope For IFRX?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxNSXdoUnBQM2pUNG5XSGpoblI2emdqcUxfbEdVRnZTRXRvMWZyYUhGZW5LNkltRHRpaDNWaG5waTFzUkVGZGtpNDEyMlBMM3Q3RmlKZkw1N2N5QjNSTjNoYUVfSF9xSzM4WnRGVmdJZHdBSEV4UFJJaFZEczlQUDVlTmc5bmNpeGVpU212dnpOSFh1UFAyUklpOXNLOV91a3NuM3VJazhnN3FtY1h5Y094VjN1YmU1U2xsV0hhbDBhRXc?oc=5","date":"2025-12-30","type":"pipeline","source":"Stock Titan","summary":"New analysis hints at progress for rare, painful skin ulcers in PG - Stock Titan","headline":"New analysis hints at progress for rare, painful skin ulcers in PG","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-12","type":"trial","source":"simplywall.st","summary":"InflaRx (IFRX): Assessing Valuation After Positive Phase 2a Results for INF904 in HS and CSU - simplywall.st","headline":"InflaRx (IFRX): Assessing Valuation After Positive Phase 2a Results for INF904 in HS and CSU","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMib0FVX3lxTFBPWnJKMnNtZy1wQjVZWEtlc20xRWl3SmZTbXYwVkxsWDh5RUlERlpaT25BbGF0ZDZXc3ZUM2ZXRVdKRk5DOVc2WnZFRkhOOVV2NnFMZnhyLUZZZjZDRW54cnZrSHgzZzVvYWkzajJDTQ?oc=5","date":"2025-11-08","type":"trial","source":"StocksToTrade","summary":"InflaRx Prepares for Key Phase 2a Clinical Trial Results - StocksToTrade","headline":"InflaRx Prepares for Key Phase 2a Clinical Trial Results","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxPVWNCMHQtMmJnZlZ0RnMzSkJESkxhdGFvSEpKc1ZOdUVOdGU0dmV1OWhfaUZmbEFTSGRIdFdoWjFnYkpJdFJnLWxObmFKTTNnMm5Yd0tQMzhmOXVUS3FkTHUwZVNhVVZjSE45TDE5WW1WVHVfbWxPRF9oZkl2ekhxZDg2VmtpY1FT?oc=5","date":"2025-11-07","type":"trial","source":"Yahoo Finance","summary":"InflaRx to Announce Topline Data from Phase 2a Clinical Trial of INF904 in Hidradenitis Suppurativa and Chronic Spontaneous Urticaria - Yahoo Finance","headline":"InflaRx to Announce Topline Data from Phase 2a Clinical Trial of INF904 in Hidradenitis Suppurativa and Chronic Spontane","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE9wSzItdHg3aGFLdkFOUFR4azYtTmtqSXNsekNudVpqaDI3SkEtUTJqRzYzMldhNmhHb2ttT3pzdHY0NWp6N1B5ZEVTTlRDQkJQNk5v?oc=5","date":"2025-04-24","type":"pipeline","source":"Stock Titan","summary":"IFRX Stock Price, News & Analysis - Stock Titan","headline":"IFRX Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZkFVX3lxTFA5Zk55ejMyckdEWjlDbnNZZ2NtZDNMeTRkcFJuc1p0c1NTUHN3RXpoNjBQWnRDcTRVNVNVNmk0TU8yOUpPbTdMU2hFQXNPdGhhQnlvSXlKcUJQSlJkR25NazVnQW9IQQ?oc=5","date":"2024-05-11","type":"pipeline","source":"MarketBeat","summary":"InflaRx (IFRX) Stock Forecast and Price Target 2026 $IFRX - MarketBeat","headline":"InflaRx (IFRX) Stock Forecast and Price Target 2026 $IFRX","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMia0FVX3lxTE8xNVhnYWtvemQxa3RQenpjU1RQdWVYR3lFREJSRG1tZjRRcjVHTlhKY2JQN2l6N1Q1SzRzQ3dlcF9ScHd2dC1sc1FUQ3pHQ2NMZWp4R1U0U1JtR2dURnVHN1hPdnAwSnlOS0Jr?oc=5","date":"2021-07-18","type":"earnings","source":"Zacks Investment Research","summary":"What date does InflaRx's (IFRX) report Earnings - Earnings Calendar & Announcement - Zacks Investment Research","headline":"What date does InflaRx's (IFRX) report Earnings - Earnings Calendar & Announcement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxNQXRrbjMyNXB5NnNUQWNaZWdlWjdkZHJGamlVWEYzT0E4QVoxME1EeW1hUnFjV2M3NUtnaDRNbG5ISnV3cjAzWkVyU19TbEVGTC1pRjE5cTdSNUtuZ2syVWRIVmxZZG9KVFdfUTNOY0REbWN4NGJUUEExaWpHVWkzYg?oc=5","date":"2020-04-28","type":"pipeline","source":"MarketBeat","summary":"Top InflaRx (IFRX) Competitors 2026 - MarketBeat","headline":"Top InflaRx (IFRX) Competitors 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZkFVX3lxTE1yWWJnQ1lBTFZBVjdNcjlZRUNJM1RVTDY1ZGxmSUZDNGhOeTBaTEJfQjhWWmNHd21CU21QSk5kSjIyWGRJWDlXcklEanF2THlQOFBXSlg1UnczcVhrT29XUW5RckllZw?oc=5","date":"2018-06-21","type":"earnings","source":"MarketBeat","summary":"InflaRx (IFRX) Earnings Date and Reports 2026 $IFRX - MarketBeat","headline":"InflaRx (IFRX) Earnings Date and Reports 2026 $IFRX","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiUkFVX3lxTE1RVkgxUEdDbXdnQ1NEaDVxNUxiSThRalQ4WGZ6Y2R2RXJFckZTU2JCcjEyc0pjdlJ0aVZZN0ZZcmtXNk9Ka0tlcVFWSGQtNTRPLWc?oc=5","date":"2017-11-04","type":"pipeline","source":"Yahoo Finance Singapore","summary":"InflaRx N.V. (IFRX) stock price, news, quote and history - Yahoo Finance Singapore","headline":"InflaRx N.V. (IFRX) stock price, news, quote and history","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Biogen","Sanofi","Novartis"],"therapeuticFocus":["Immunology","Anti-Complement"],"financials":{"source":"yahoo_finance","revenue":34265.1869433,"revenuePeriod":"2025-12-31","revenueHistory":[{"period":"2025-12-31","value":34265.1869433},{"period":"2024-12-31","value":193678.73847270003},{"period":"2023-12-31","value":73702.1028627},{"period":"2022-12-31","value":0}],"grossProfit":-8455942.7637741,"grossProfitHistory":[{"period":"2025-12-31","value":-8455942.7637741},{"period":"2024-12-31","value":-3681366.8253750005},{"period":"2023-12-31","value":-548099.2995039},{"period":"2022-12-31","value":0}],"rdSpend":30047649.5567484,"rdSpendHistory":[{"period":"2025-12-31","value":30047649.5567484},{"period":"2024-12-31","value":41312963.81809711},{"period":"2023-12-31","value":47925386.720583305},{"period":"2022-12-31","value":43838890.221987}],"sgaSpend":20519603.9883783,"operatingIncome":-56374969.6712682,"operatingIncomeHistory":[{"period":"2025-12-31","value":-56374969.6712682},{"period":"2024-12-31","value":-61805582.993369706},{"period":"2023-12-31","value":-52096794.4342008},{"period":"2022-12-31","value":-37661059.609568104}],"netIncome":-53310490.696854,"netIncomeHistory":[{"period":"2025-12-31","value":-53310490.696854},{"period":"2024-12-31","value":-53813553.781368606},{"period":"2023-12-31","value":-49845244.198754705},{"period":"2022-12-31","value":-34444639.0462473}],"eps":-0.68,"epsHistory":[{"period":"2025-12-31","value":-0.68},{"period":"2024-12-31","value":-0.78},{"period":"2023-12-31","value":-0.78},{"period":"2022-12-31","value":-0.67}],"cash":18717489.500955302,"cashHistory":[{"period":"2025-12-31","value":18717489.500955302},{"period":"2024-12-31","value":21467266.372314002},{"period":"2023-12-31","value":14915821.273614902},{"period":"2022-12-31","value":19001581.7909022}],"totalAssets":64505019.911417104,"totalLiabilities":15957378.517438801,"totalDebt":1048967.2905588,"equity":48547641.393978305,"operatingCashflow":-41255056.107770406,"operatingCashflowHistory":[{"period":"2025-12-31","value":-41255056.107770406},{"period":"2024-12-31","value":-56725105.18556701},{"period":"2023-12-31","value":-44174025.7362738},{"period":"2022-12-31","value":-39419178.7698531}],"capex":-135156.54216420001,"capexHistory":[{"period":"2025-12-31","value":-135156.54216420001},{"period":"2024-12-31","value":-54755.84116530001},{"period":"2023-12-31","value":-94742.99073},{"period":"2022-12-31","value":-189709.11230130002}],"freeCashflow":-41390212.649934605,"dividendsPaid":null,"buybacks":null,"employees":65,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":3461439.2551056,"ebit":-12412328.280957902,"ebitda":-12306149.542555202,"period":"2025-12-31","revenue":-39639.0187233,"epsBasic":null,"netIncome":-12432702.1127499,"rdExpense":6145658.8834212,"epsDiluted":null,"grossProfit":-5715352.808310601,"operatingIncome":-15019674.077436302},{"sga":4425669.396063901,"ebit":-14292580.618910702,"ebitda":-14176000.0113408,"period":"2025-09-30","revenue":27838.785069,"epsBasic":-0.18,"netIncome":-14323702.114262702,"rdExpense":7290683.417047501,"epsDiluted":-0.18,"grossProfit":27449.7663771,"operatingIncome":-11071267.532221502},{"sga":4906542.0600000005,"ebit":-16729068.938616902,"ebitda":-16594723.1441169,"period":"2025-06-30","revenue":46065.4205976,"epsBasic":-0.21,"netIncome":-16841438.0975853,"rdExpense":8414651.875890601,"epsDiluted":-0.21,"grossProfit":-2757185.7498693,"operatingIncome":-14982657.7222665},{"sga":7617503.510766901,"ebit":-9707872.6713177,"ebitda":-9574927.5777534,"period":"2025-03-31","revenue":0,"epsBasic":-0.13,"netIncome":-9712648.3722561,"rdExpense":8196654.212164801,"epsDiluted":-0.13,"grossProfit":-10853.971971300001,"operatingIncome":-15192918.2364534},{"sga":5508578.2754349,"ebit":-5966113.322529901,"ebitda":-5836747.6682208,"period":"2024-12-31","revenue":-494.15887890000005,"epsBasic":null,"netIncome":-5971696.2664596,"rdExpense":8066664.7260795,"epsDiluted":null,"grossProfit":-3295961.4512349004,"operatingIncome":-11405924.074545301},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":-0.3,"netIncome":null,"rdExpense":null,"epsDiluted":-0.3,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":2.42,"previousClose":2.52,"fiftyTwoWeekHigh":2.95,"fiftyTwoWeekLow":0.71,"fiftyTwoWeekRange":"0.711 - 2.949","fiftyDayAverage":1.37,"twoHundredDayAverage":1.19,"beta":0,"enterpriseValue":167290130.97495362,"forwardPE":-5.5,"priceToBook":4.04,"priceToSales":12177.74,"enterpriseToRevenue":4882.22,"enterpriseToEbitda":-3.38,"pegRatio":0,"ebitda":-49565238.3574092,"ebitdaMargin":0,"freeCashflow":-16762139.032101301,"operatingCashflow":-33517523.391300004,"totalDebt":961481.3091804001,"debtToEquity":2.2,"currentRatio":4.16,"returnOnAssets":-39.1,"returnOnEquity":-79.9,"analystRating":"1.6 - Buy","recommendationKey":"buy","numberOfAnalysts":7,"targetMeanPrice":7.11,"targetHighPrice":13.9,"targetLowPrice":2.98,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":2.9,"institutionHeldPercent":13.2,"sharesOutstanding":147292859,"floatShares":60014640,"sharesShort":1992416,"shortRatio":1.44,"shortPercentOfFloat":2.8,"epsTrailing":-0.74,"epsForward":-0.44,"revenuePerShare":0,"bookValue":0.6,"officers":[{"age":52,"name":"Prof. Niels C. Riedemann M.D., Ph.D.","title":"Co-Founder, CEO & Executive Director"},{"age":55,"name":"Prof. Renfeng  Guo M.D.","title":"Co-Founder, Chief Scientific Officer & Executive Director"},{"age":60,"name":"Dr. Thomas  Taapken Ph.D.","title":"Chief Financial Officer"},{"age":59,"name":"Ms. Derval  O'Carroll","title":"Senior VP and Global Head of Regulatory Affairs & Compliance"},{"age":59,"name":"Dr. Camilla  Chong M.D.","title":"Chief Medical Officer"},{"age":null,"name":"Mr. Jan  Medina CFA","title":"Head of Investor Relations & VP"},{"age":null,"name":"Mr. Christian  Schmid","title":"VP and Head of Legal Affairs & General Counsel"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.inflarx.de","phone":"49 3641 508 180"}}